Preventing Stem Cell Transplant Complications With a Blood Separator Machine
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin · ALL (Acute B-Lymphoblastic Leukemia) · AML (Acute Myelogenous Leukemia
Bottom Line
View on ClinicalTrials.gov: NCT01866839 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Graft Manipulation (CD34+ Selection) (Device)
- Age
- Pediatric, Adult, Older Adult · 2+ yrs
- Sex
- All
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival |
36 | — |
| SECONDARY Disease Free Survival at 2 Years |
60.8 | — |
| SECONDARY Disease Progression |
11 | — |
| SECONDARY Incidence of Acute GVHD |
26 | — |
| SECONDARY Incidence of Chronic GVHD |
14 | — |
| SECONDARY Median Time to ANC>500/mm3 |
12 | — |
| SECONDARY Median Time to Platelets>20K/mm3 |
15 | — |
| SECONDARY Severity of Acute GVHD |
1 | — |
| SECONDARY Severity of Acute GVHD |
1 | — |
| SECONDARY Severity of Acute GVHD |
1 | — |
| SECONDARY Severity of Acute GVHD |
1 | — |
| SECONDARY Severity of Chronic GVHD |
4 | — |
| SECONDARY Severity of Chronic GVHD |
4 | — |
Summary
Eligibility Criteria
- INCLUSION CRITERIA RECIPIENT
5.1.1 Ages 10-80 years inclusive
5.1.2 Any one of the following hematologic conditions, confirmed by pathology, meeting a standard indication for allogeneic stem cell transplant:
5.1.2.1 Chronic myelogenous leukemia (CML): Subjects under the age of 21 in chronic phase OR Subjects ages 10-80 in chronic phase who have failed or are intolerant to treatment with second generation tyrosine inhibitors OR Subjects ages 10-80 in accelerated phase or blast transformation. OR
5.1.2.2 Acute lymphoblastic leukemia (ALL): any of these categories: Adult ALL including standard risk; Pediatric ALL in first remission with high-risk features (presenting leukocyte count >100,000/cu mm, karyotypes t(9; 22), t4, t19, t11, biphenotypic leukemia). All second or subsequent remissions, primary induction failure, partially responding or untreated relapse. OR
5.1.2.3 Acute myelogenous leukemia (AML): AML in first remission - except AML with good risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), c-kit unmutated AML t (8; 21). All AML in second or subsequent remission, primary induction failure and resistant relapse. OR
5.1.2.4 Myelodysplastic syndromes(MDS): any of these categories - refractory anemia with transfusion dependence, refractory anemia with ANC 10 times ULN
5.2.7 Total bilirubin > 5 times ULN
5.2.8 Estimated GFR < 15 mL/min
5.2.9 Recipients who have active infections with HIV or active hepatitis C (HCV)
INCLUSION CRITERIA DONOR
5.3.1 Related donor, HLA identical (6/6) with recipient
5.3.2 Weight greater than or equal to 18 kg
5.3.3 Age greater than or equal to 2 or less than or equal to 80 years old
5.3.4 For adults: ability to comprehend the investigational nature of the study and provide informed consent. For minors: written informed consent from one parent or guardian and informed assent: The process will be explained to the minor on a level of complexity appropriate for their age and ability to comprehend.
EXCLUSION CRITERIA DONOR (any of the following)
5.4.1 Pregnant or breast-feeding. Lactating donors are permitted provided breast milk is discarded during the days filgrastim (G-CSF) is given
5.4.2 Unfit to receive G-CSF and undergo apheresis (abnormal blood counts, history of stroke, uncontrolled hypertension)
5.4.3 Sickling hemoglobinopathy including HbSS, HbSC
5.4.4 Donors who are positive for HIV, active hepatitis B (HBV), hepatitis C (HCV) or human Tcell lymphotropic virus (HTLV-I/II)
5.4.5 Severe psychiatric illness or mental deficiency sufficiently severe as to make compliance with the donation process unlikely, and making informed consent impossible.
Data sourced from ClinicalTrials.gov (NCT01866839). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.